文献速递糖尿病

钠-葡萄糖协同转运蛋白2抑制剂与成人糖尿病前期新发2型糖尿病:随机对照试验的系统评价与Meta分析

Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

该系统评价与Meta分析纳入4项随机对照试验共5655例糖尿病前期成人,评估SGLT2抑制剂对比安慰剂对新发糖尿病风险的影响。SGLT2抑制剂与新发糖尿病风险降低显著相关(相对风险0.79,95%CI 0.68-0.93),达格列净与恩格列净的相对风险分别为0.68(95%CI 0.52-0.89)和0.87(95%CI 0.72-1.04),严重低血糖频率未升高。

要点

  • SGLT2抑制剂与糖尿病前期成人新发2型糖尿病风险降低相关(相对风险0.79,95%CI 0.68-0.93)。
  • 达格列净相对风险0.68(95%CI 0.52-0.89),恩格列净相对风险0.87(95%CI 0.72-1.04)。
  • SGLT2抑制剂组严重低血糖频率较安慰剂组未升高。

核心结论

  • 在伴有心力衰竭或慢性肾脏病的糖尿病前期成人中,SGLT2抑制剂与新发2型糖尿病风险降低相关。
  • 这些发现提示SGLT2抑制剂在预防糖尿病前期高危人群发生糖尿病方面具有潜在用途。

研究设计与样本

  • 随机对照试验的系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials至2022年2月11日。
  • 纳入4项随机对照试验,共5655例糖尿病前期成人,比较SGLT2抑制剂与安慰剂对新发糖尿病风险的影响,采用随机效应模型计算风险比及95%CI。

主要发现

  • SGLT2抑制剂与新发糖尿病风险降低显著相关(相对风险0.79,95%CI 0.68-0.93)。
  • 达格列净的新发糖尿病相对风险为0.68(95%CI 0.52-0.89),恩格列净为0.87(95%CI 0.72-1.04),异质性P=.14。
  • SGLT2抑制剂组严重低血糖频率较安慰剂组未升高。

关键数值与推荐

  • SGLT2抑制剂对比安慰剂的新发糖尿病相对风险0.79(95%CI 0.68-0.93)。
  • 达格列净新发糖尿病相对风险0.68(95%CI 0.52-0.89),恩格列净0.87(95%CI 0.72-1.04),异质性P=.14。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The preventive effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors for new-onset diabetes was investigated in secondary analyses of several randomized controlled trials (RCTs). However, the results were inconsistent. OBJECTIVE: This work aimed to synthesize available evidence and evaluate whether SGLT2 inhibitors are effective in preventing new-onset diabetes. METHODS: In this systematic review and meta-analysis of RCTs, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched through February 11, 2022. Two independent authors screened the search results and extracted summary data from eligible RCTs (including original and post hoc analyses) comparing SGLT2 inhibitors and placebo for the risk of new-onset diabetes among adults with prediabetes. Meta-analysis was conducted using random-effects models to calculate risk ratios and 95% CIs. RESULTS: We included 4 RCTs with 5655 participants who had prediabetes. Based on the random-effects meta-analysis, SGLT2 inhibitors were significantly associated with a lower risk of new-onset diabetes (relative risk, 0.79; 95% CI, 0.68-0.93). The relative risks of new-onset diabetes in dapagliflozin and empagliflozin were 0.68 (95% CI, 0.52-0.89) and 0.87 (95% CI, 0.72-1.04), respectively (P-for-heterogeneity = .14). The frequency of severe hypoglycemia was not elevated in the SGLT2 inhibitors group compared to the placebo group. CONCLUSION: In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of new-onset type 2 diabetes among adults with prediabetes and heart failure or chronic kidney disease. These findings indicate the potential usefulness of SGLT2 inhibitors in preventing diabetes among high-risk populations with prediabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mori Y, Duru OK, Tuttle KR, et al. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2022. PMID: 36217306. doi:10.1210/clinem/dgac591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。